Biomaterials Advances, volume 140, pages 213077

Advances in aptamer-based drug delivery vehicles for cancer therapy

Kousar Ghasemii 1
Mahdieh Darroudi 2
Ilnaz Rahimmanesh 3
Matineh Ghomi 4
Mahnaz Hassanpour 5
Esmaeel Sharifi 6, 7
Satar Yousefiasl 6
Sepideh Ahmadi 8
Ali Zarrabi 9
A Borzacchiello 10
Mohammad Rabiee 11
Navid Rabiee 14, 15
7
 
Institute for Polymers, Composites and Biomaterials, National Research Council (IPCB-CNR), Naples 80125, Italy
10
 
Institute for Polymers, Composites and Biomaterials, National Research Council, IPCB-CNR, 80125 Naples, Italy
Publication typeJournal Article
Publication date2022-09-01
Quartile SCImago
Quartile WOS
Impact factor
ISSN27729508
Bioengineering
Biomaterials
Biomedical Engineering
Abstract
Overall, aptamers are special classes of nucleic acid-based macromolecules that are beginning to investigate because of their capability of avidity binding to a specific target for clinical use. Taking advantage of target-specific medicine led to more effective therapeutic and limitation of side effects of drugs. Herein, we discuss several aptamers and their binding capability and capacity for selecting tumor biomarkers and usage of them as targeting ligands for the functionalization of nanomaterials. We review recent applications based on aptamers and several nanoparticles to rise efficacy and develop carrier systems such as graphene oxide, folic acid, gold, mesopores silica, and various polymers and copolymer, polyethylene glycol, cyclodextrin, chitosan. The nanocarriers have been characterized by particle size, zeta potential, aptamer conjugation, and drug encapsulation efficiency. Hydrodynamic diameter and Zeta potential can used in order to monitor aptamers' crosslinking, in-vitro drug release, intracellular delivery of nanocarriers, and cellular cytotoxicity assay. Also, they are studied for cellular uptake and internalization to types of cancer cell lines such as colorectal, breast, prostate, leukemia and etc. The results are investigated in in-vivo cytotoxicity assay and cell viability assay. Targeted cancer therapy seems a good and promising strategy to overcome the systemic toxicity of chemotherapy.

Top-30

Citations by journals

1
Molecules
1 publication, 6.67%
Materials Today Bio
1 publication, 6.67%
International Journal of Biological Macromolecules
1 publication, 6.67%
Cancers
1 publication, 6.67%
ACS Symposium Series
1 publication, 6.67%
ACS Omega
1 publication, 6.67%
Applied Materials Today
1 publication, 6.67%
Applied Research
1 publication, 6.67%
Russian Chemical Reviews
1 publication, 6.67%
Bioorganic Chemistry
1 publication, 6.67%
ACS applied materials & interfaces
1 publication, 6.67%
Bioactive Materials
1 publication, 6.67%
Coordination Chemistry Reviews
1 publication, 6.67%
1

Citations by publishers

1
2
3
4
5
6
7
Elsevier
7 publications, 46.67%
American Chemical Society (ACS)
3 publications, 20%
Multidisciplinary Digital Publishing Institute (MDPI)
2 publications, 13.33%
Wiley
1 publication, 6.67%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 6.67%
Springer Nature
1 publication, 6.67%
1
2
3
4
5
6
7
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Ghasemii K. et al. Advances in aptamer-based drug delivery vehicles for cancer therapy // Biomaterials Advances. 2022. Vol. 140. p. 213077.
GOST all authors (up to 50) Copy
Ghasemii K., Darroudi M., Rahimmanesh I., Ghomi M., Hassanpour M., Sharifi E., Yousefiasl S., Ahmadi S., Zarrabi A., Borzacchiello A., Rabiee M., Paiva‐Santos A. C., Rabiee N. Advances in aptamer-based drug delivery vehicles for cancer therapy // Biomaterials Advances. 2022. Vol. 140. p. 213077.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.bioadv.2022.213077
UR - https://doi.org/10.1016/j.bioadv.2022.213077
TI - Advances in aptamer-based drug delivery vehicles for cancer therapy
T2 - Biomaterials Advances
AU - Ghasemii, Kousar
AU - Darroudi, Mahdieh
AU - Rahimmanesh, Ilnaz
AU - Ghomi, Matineh
AU - Hassanpour, Mahnaz
AU - Sharifi, Esmaeel
AU - Yousefiasl, Satar
AU - Ahmadi, Sepideh
AU - Zarrabi, Ali
AU - Borzacchiello, A
AU - Rabiee, Mohammad
AU - Paiva‐Santos, Ana Cláudia
AU - Rabiee, Navid
PY - 2022
DA - 2022/09/01 00:00:00
PB - Elsevier
SP - 213077
VL - 140
SN - 2772-9508
ER -
BibTex
Cite this
BibTex Copy
@article{2022_Ghasemii,
author = {Kousar Ghasemii and Mahdieh Darroudi and Ilnaz Rahimmanesh and Matineh Ghomi and Mahnaz Hassanpour and Esmaeel Sharifi and Satar Yousefiasl and Sepideh Ahmadi and Ali Zarrabi and A Borzacchiello and Mohammad Rabiee and Ana Cláudia Paiva‐Santos and Navid Rabiee},
title = {Advances in aptamer-based drug delivery vehicles for cancer therapy},
journal = {Biomaterials Advances},
year = {2022},
volume = {140},
publisher = {Elsevier},
month = {sep},
url = {https://doi.org/10.1016/j.bioadv.2022.213077},
pages = {213077},
doi = {10.1016/j.bioadv.2022.213077}
}
Found error?